SPY332.80-2.77 -0.83%
DIA277.19-0.95 -0.34%
IXIC10,782.82-185.53 -1.69%

Regulus Therapeutics Q3 EPS $(0.26) Up From $(1.18) YoY, Sales $18K, Same YoY

Regulus Therapeutics (NASDAQ:RGLS) reported quarterly losses of $(0.26) per share. This is a 77.97 percent increase over losses of $(1.18) per share from the same period last year. The company reported $18 thousand in

Benzinga · -

Regulus Therapeutics (NASDAQ:RGLS) reported quarterly losses of $(0.26) per share. This is a 77.97 percent increase over losses of $(1.18) per share from the same period last year. The company reported $18 thousand in sales this quarter. This is the same as the same period last year.